The best indicator for Biotech (IBB)
We backtested 382 indicators across daily, weekly and hourly charts on real Biotech (IBB) history. Here's what actually worked — risk-adjusted over the full backtest, with costs, and checked out-of-sample.
Where Biotech (IBB) stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
LSMA 10/30 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for Biotech (IBB) over ~25.7 years — trailing buy-and-hold by 0.7% CAGR.
Biotech (IBB) on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Biotech (IBB) — trailing buy-and-hold by 3.3% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | LSMA 10/30 Cross ✓ | Weekly | 7.1% | 0.52 | -29.2% | 55.4% | 56 | -0.7% |
| 2 | Zero-Lag LSMA ✓ | Weekly | 6.9% | 0.51 | -37.2% | 52.5% | 99 | -0.8% |
| 3 | Least Squares MA ✓ | Weekly | 6.6% | 0.5 | -39.9% | 51.5% | 97 | -1.1% |
| 4 | QQE ✓ | Weekly | 8.9% | 0.5 | -44.9% | 55.6% | 72 | 1.1% |
| 5 | Trend Regularity Adaptive MA ✓ | Weekly | 6.3% | 0.49 | -28.8% | 30.8% | 26 | -1.5% |
| 6 | Negative Volume Index ✓ | Daily | 8.0% | 0.48 | -39.2% | 54.8% | 42 | 0.5% |
| 7 | CCI (50) ✓ | Daily | 6.8% | 0.48 | -33.8% | 38.0% | 179 | -0.7% |
| 8 | Bollinger Mean-Reversion ✓ | Weekly | 5.2% | 0.48 | -31.0% | 72.7% | 22 | -2.5% |
| 9 | Fibonacci Bands ✓ | Weekly | 5.2% | 0.48 | -31.0% | 72.7% | 22 | -2.5% |
| 10 | Parabolic SAR ✓ | Weekly | 6.3% | 0.47 | -42.1% | 53.3% | 60 | -1.4% |
| 11 | EMA 8/21 Cross ✓ | Daily | 6.5% | 0.46 | -30.3% | 40.3% | 144 | -1.0% |
| 12 | Markov Regime ✓ | Weekly | 7.1% | 0.46 | -37.5% | 55.6% | 27 | -0.7% |
| 13 | Guppy Multiple MA ✓ | Daily | 6.2% | 0.45 | -39.5% | 42.6% | 101 | -1.3% |
| 14 | Accelerator Oscillator ✓ | Weekly | 5.8% | 0.45 | -24.0% | 53.2% | 79 | -1.9% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
What it would take to beat buy & hold on Biotech (IBB)
17 of 665 tested setups beat buy-and-hold on Biotech (IBB) outright. Another 122 could get there with leverage they would survive — but 104 would be liquidated by their own drawdown before they caught it.
| Indicator | Beats B&H unlevered | Leverage needed | Leverage survived |
|---|---|---|---|
| Bollinger Mean-Reversion | 1 | 1.11× | 5.57× |
| Fibonacci Bands | 1 | 1.11× | 5.57× |
| Connors RSI-2 | 1 | 1.17× | 5.62× |
| Projection Bands | 1 | 1.47× | 3.46× |
| Williams %R | 1 | 3.0× | 3.46× |
| Connors RSI | 1 | 3.89× | 4.93× |
Out-of-sample, costs included. A setup is only listed if the leverage it needs is less than the leverage its own worst drawdown survives — when it isn't, no amount of leverage gets there. Volatility drag isn't modelled, so these are the optimistic case. Every indicator, ranked this way
For Biotech (IBB), LSMA 10/30 Cross on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More etf
Get alerted when Biotech’s signal flips
We track Biotech daily. Its backtested best indicator, LSMA 10/30 Cross (Weekly), is flat right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.